language Türkçe
Article 2022 · 9 citations

Preparation and Characterization of Nanosuspensions of Triiodoaniline Derivative New Contrast Agent, and Investigation into Its Cytotoxicity and Contrast Properties

Koca, Mehmet, Ozakar, Rukiye Sevinc, Ozakar, Emrah, Sade, Recep, Pirimoglu, Berhan, Ozek, Nihal Simsek, Aysin, Ferhunde

Abstract

Iodine-based contrast agents have limitations such as rapid clearance, potential renal toxicity, non-specific blood pool distribution, headache, and adverse events. Nowadays, it is quite common to work with nanosized systems in order to eliminate the side effects of contrast agents. This study aims to synthesize a new iodinated contrast agent, prepare its nanosuspension by using the nanoprecipitation method, investigate its cytotoxicity, and compare its contrast properties with iohexol and iopromide through in-vitro experiments. The values of nanosuspension particle size and zeta potential have been found to be similar to 400nmand similar to (-) 15mV, respectively. In-vitro cellular viability findings indicated that the nanosuspension has lower cytotoxicity than the iohexol and iopromide. In the computed tomography (CT) imaging study of contrast features of nanosuspensions and two commercial agents, which involved 86 CT examinations using 31 parameters and two different devices, it was found that iodine had a stronger presence in its nanosuspension form than in iohexol and iopromide, which were the other two commercial contrast agents, when used in equal amounts. Thus in the case of nanosuspensions contrast brightness was achieved by using less iodine, while the same brightness could be obtained with higher doses of iohexol and iopromide. CT imaging therefore be done without much chemical use, which indicates that it may witness fewer side effects in the future.

Keywords
Radiocontrast Agent CT Imaging Cytotoxicity Nanosuspension Synthesis Viscosity Stability COMPUTED-TOMOGRAPHY MEDIA FORMULATION VISCOSITY IMPACT IODINE
WoS Categories
Pharmacology & Pharmacy
Sustainable Development Goals
Citation
Journal
IRANIAN JOURNAL OF PHARMACEUTICAL RESEARCH
Year
2022
Volume
21
Issue
1
ISSN
1735-0328
eISSN
1726-6890
DOI
10.5812/ijpr.123824
WoS UID
WOS:000880130500001
Open via DOI